Genscript Biotech Valuation
Is 1548 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1548 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1548 (HK$10.96) is trading below our estimate of fair value (HK$11.52)
Significantly Below Fair Value: 1548 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1548?
Key metric: As 1548 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 1548's PS Ratio? | |
|---|---|
| PS Ratio | 3x |
| Sales | US$1.01b |
| Market Cap | US$3.02b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.7x |
| Enterprise Value/EBITDA | -9.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 1548's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5x | ||
2268 WuXi XDC Cayman | 10.6x | 26.0% | HK$32.0b |
2269 WuXi Biologics (Cayman) | 3.3x | 10.6% | HK$60.7b |
1521 Frontage Holdings | 1.2x | 13.6% | HK$2.4b |
2576 Zhejiang Taimei Medical Technology | 4.8x | 13.6% | HK$3.0b |
1548 Genscript Biotech | 3x | 39.9% | HK$23.5b |
Price-To-Sales vs Peers: 1548 is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (5x).
Price to Sales Ratio vs Industry
How does 1548's PS Ratio compare vs other companies in the Asian Life Sciences Industry?
| 8 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 8 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 1548 is good value based on its Price-To-Sales Ratio (3x) compared to the Asian Life Sciences industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is 1548's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3x |
| Fair PS Ratio | 10.3x |
Price-To-Sales vs Fair Ratio: 1548 is good value based on its Price-To-Sales Ratio (3x) compared to the estimated Fair Price-To-Sales Ratio (10.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$10.96 | HK$23.34 +112.9% | 18.7% | HK$29.09 | HK$16.00 | n/a | 10 |
| Nov ’25 | HK$11.70 | HK$23.28 +99.0% | 18.7% | HK$29.02 | HK$16.00 | n/a | 10 |
| Oct ’25 | HK$13.94 | HK$23.56 +69.0% | 18.8% | HK$29.12 | HK$16.00 | n/a | 10 |
| Sep ’25 | HK$11.82 | HK$23.56 +99.3% | 18.8% | HK$29.12 | HK$16.00 | n/a | 10 |
| Aug ’25 | HK$12.16 | HK$24.14 +98.5% | 27.6% | HK$30.94 | HK$10.60 | n/a | 9 |
| Jul ’25 | HK$8.32 | HK$25.03 +200.9% | 27.4% | HK$33.03 | HK$10.60 | n/a | 10 |
| Jun ’25 | HK$10.00 | HK$27.73 +177.3% | 17.7% | HK$32.98 | HK$16.00 | n/a | 10 |
| May ’25 | HK$11.64 | HK$28.85 +147.8% | 10.6% | HK$33.06 | HK$23.00 | n/a | 10 |
| Apr ’25 | HK$14.50 | HK$28.85 +98.9% | 10.6% | HK$33.06 | HK$23.00 | n/a | 10 |
| Mar ’25 | HK$15.50 | HK$30.55 +97.1% | 5.4% | HK$33.03 | HK$27.02 | n/a | 10 |
| Feb ’25 | HK$14.10 | HK$30.55 +116.7% | 5.4% | HK$33.03 | HK$27.02 | n/a | 10 |
| Jan ’25 | HK$19.86 | HK$30.95 +55.9% | 6.7% | HK$34.73 | HK$27.00 | n/a | 10 |
| Dec ’24 | HK$21.50 | HK$30.90 +43.7% | 6.7% | HK$34.67 | HK$26.96 | n/a | 10 |
| Nov ’24 | HK$22.85 | HK$29.78 +30.3% | 12.3% | HK$34.81 | HK$23.94 | HK$11.70 | 9 |
| Oct ’24 | HK$20.65 | HK$28.65 +38.8% | 17.0% | HK$34.83 | HK$18.45 | HK$13.94 | 10 |
| Sep ’24 | HK$18.38 | HK$28.47 +54.9% | 16.8% | HK$34.90 | HK$18.49 | HK$11.82 | 10 |
| Aug ’24 | HK$20.30 | HK$29.19 +43.8% | 19.1% | HK$36.81 | HK$18.39 | HK$12.16 | 10 |
| Jul ’24 | HK$17.60 | HK$29.16 +65.7% | 19.0% | HK$36.96 | HK$18.47 | HK$8.32 | 10 |
| Jun ’24 | HK$17.54 | HK$28.51 +62.5% | 21.0% | HK$35.01 | HK$18.46 | HK$10.00 | 6 |
| May ’24 | HK$20.60 | HK$27.98 +35.8% | 22.8% | HK$35.10 | HK$18.50 | HK$11.64 | 5 |
| Apr ’24 | HK$16.80 | HK$31.58 +87.9% | 21.3% | HK$41.00 | HK$20.50 | HK$14.50 | 5 |
| Mar ’24 | HK$22.75 | HK$31.61 +38.9% | 21.3% | HK$41.00 | HK$20.50 | HK$15.50 | 5 |
| Feb ’24 | HK$28.20 | HK$31.72 +12.5% | 22.0% | HK$41.88 | HK$20.44 | HK$14.10 | 5 |
| Jan ’24 | HK$24.85 | HK$30.84 +24.1% | 24.6% | HK$41.76 | HK$20.38 | HK$19.86 | 4 |
| Dec ’23 | HK$19.58 | HK$30.48 +55.7% | 24.9% | HK$41.78 | HK$20.39 | HK$21.50 | 4 |
| Nov ’23 | HK$20.50 | HK$30.80 +50.3% | 28.6% | HK$42.00 | HK$20.50 | HK$22.85 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Consun Pharmaceutical Group
HK$6.5b
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
1681
HK$7.95
7D
-5.9%
1Y
76.3%
Innovent Biologics
HK$64.5b
A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.
1801
HK$39.15
7D
1.7%
1Y
-14.5%
United Laboratories International Holdings
HK$18.9b
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
3933
HK$10.42
7D
3.6%
1Y
31.9%